Cancer Breakthrough 20 Years in the Making

Last month, Penn Medicine put out a press release heralding a "cancer treatment breakthrough 20 years in the making." In a small clinical trial, three patients with advanced chronic lymphocytic leukemia (CLL) were treated with genetically engineered versions of their own T cells. Just a few weeks after treatment the tumors had disappeared, and the patients remained in remission for a year before the study was published.

The release didn't, however, explain those "20 years in the making." In 1989, Prof. Zelig Eshhar of the Weizmann Institute's Immunology Department first published a paper describing a method of creating gene-modified T cells by adding on chimeric molecules that functioned as receptors with the specificity of an antibody. The idea, from the beginning, was that these immune cells could be programmed to identify and coordinate an attack against such cells as cancer cells, which generally manage to evade the immune system. The engineering method used by the Penn team is the one Eshhar began developing in the 1980s. For Eshhar, the new study is proof of concept; it had previously been shown to work in mice. Now that the method has been successfully used in humans - and the results even better than anyone dared hope - it can be tried on a wider scale for other types of cancer.

If the idea seems futuristic now, it was downright science fiction, then. More importantly, those first chimeric T cells were created in a lab dish and sent off to attack other cells in a lab dish. Those twenty years reflect the time it takes to move from a revolutionary idea that works in the lab to a medical treatment that works on humans. In light of the many potential anti-cancer treatments that fail somewhere along the way from lab to clinic, the new study is a triumph both for the Penn team and for Eshhar and his team.

This is clearly the place to repeat our mantra about basic research: It is a long-term undertaking. There are no guarantees. No one can predict where a specific line of inquiry will eventually lead, or when. Without basic research and vision, there will be no innovative new cancer treatments.

Eshhar, by the way, recently improved on the genetically engineered T cell idea by creating them from a non-matched donor pool, rather than cells extracted from the individual patient. In mouse experiments, he and his team temporarily suppressed the immune system with a mild dose of radiation and then administered the donor chimeric T cells. Because the method destroys tumors so quickly and effectively, these cells had time to finish the job before the immune system came back online and rejected them.

How long will it take for this improved method to reach the clinic? For our answer, see paragraph four. Or keep posted here.


More like this

This study is a case study from this study (lol): Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia I imagined this scene happened in one of their lab meetings: I didnt go in-depth as to how everything was working before, so I thought I would do it now! This paper is a case…
I've made no secret how much contempt I have for Kevin Trudeau, whom I have likened to David Irving, at least with respect to his respect for the truth. He has made many, many millions of dollars selling books with titles like Natural Cures "They" Don't Want You to Know About and its followups, in…
Five kids in the first trial. Then eleven. Now thirty (ultimately 39): Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia Slowly but surely, HIV genetically modified to genetically modify relapsed acute lymphoblastic leukemia (ALL) patients T-cells are prolonging (saving?) kids…
If there's one thing that proponents of "integrative medicine" (or, as it's been called in the past, "complementary and alternative medicine," or CAM) take great pains to emphasize whenever defending their integration of prescientific and pseudoscientific medicine into medicine, it's that they do…

We have been waiting so long for good news. Will it be an expensive treatment, I wonder. Prof. Eshhar may well be a medical hero right up there with Jonas Salk, who took away the scourge I remember from my childhood, and so well current generations barely knows what polio was.

By S. Bolser (not verified) on 12 Sep 2011 #permalink

Fascinating work, and a good example of why investment in basic scientific research is so important to medical progress in the long term.

David Porter and colleagues have published a paper on CAR therapy for CLL last June in the Journal of Cancer that is available to view without subscription in PubMed Central

It gives a good -if brief - overview of some of the research leading up to the clinical trial.

there have been for quite some time now, more than 14 natural "CANCER CURES". And a few thousand herbs that can help combat the side effects of establishment medicines so called treatments i.e. cut burn poison or irradiate that can be more dangerous than the cancer itself.

Big Pharmacological Companies loose money if you can go to your backyard and grow your own cure, they use their billions to dominate the education of future doctors, so any alternative to their monopoly is promptly attacked and discredited before it is thoughtfully considered.

I'll be quick, you got anything to back that up Drew?

By Burple Nurple (not verified) on 07 Nov 2011 #permalink

I know this if off topic but I'm looking into starting my own blog and was wondering what all is required to get setup? I'm assuming having a blog like yours would cost a pretty penny? I'm not very web savvy so I'm not 100% certain. Any suggestions or advice would be greatly appreciated. Cheers

By Guess The Word Cheat (not verified) on 06 Mar 2013 #permalink

I'm not sure why you're asking me this -- We Weizmann Science Writers joined the ScienceBlogs site, which is an aggregate of individual bloggers -- and enjoy the benefits. If you write well and have a good idea for a blog, you can either try to pitch it to an existing blog site on a similar topic, or else Google "word press" and read the tutorials.